DiaMedica Inc. (DiaMedica) is a development-stage biopharmaceutical company engaged in the development of therapies for metabolic disorders, kidney dysfunction and orphan diseases. DiaMedica's lead compound, DM-199, is a recombinant human tissue kallikrein-1 protein, rhKLK-1, for the treatment of both Type I and Type II diabetes and their complications. DM-199 improves glucose control by increasing insulin sensitivity and glucose uptake, and to improve endothelial function by inducing vasodilationDM199 is evaluated in Phase 1 and Phase 2 clinical trials for assessment of safety, tolerability, pharmacokinetics and changes in diabetes markers. DiaMedica is also developing a monoclonal antibody, DM204, for the treatment of type 2 diabetes and associated complications, including hypertension. DM204 specifically target and modulate the bradykinin 2 receptor (B2R) and is in preclinical stage of development.